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Abstract The role of the phosphatidylinositol 3-kinase (PI3K)
pathway in the hyperphosphorylation of d was investigated in
SY5Y human neuroblastoma cells. Wortmannin, an inhibitor of
PI3K, induced transient (after 1 h) activation of glycogen
synthase kinase-3 (GSK-3), hyperphosphorylation of d and dose-
dependent cytotoxicity. However, continuous inactivation of
protein kinase (PK) B was observed from 1 to 24 h, suggesting
the involvement of protein kinase(s) other than PKB in the
phosphorylation and inactivation of GSK-3 after 3 h. In cells
treated with wortmannin, PKC N fragments were observed, and
the PKC activity increased after 3 h, whereas treatment of cells
with z-DEVD-fmk, an inhibitor of caspase 3, also inhibited
fragmentation of PKC N and induced continuous activation of
GSK-3. It is suggested that fragmentation of PKC N during the
process of apoptosis results in the phosphorylation and inactiva-
tion of GSK-3 and consequently inhibition of the phosphorylation
of d.
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1. Introduction
Neuro¢brillary tangles of paired helical ¢laments (PHF) are
neuropathological hallmarks of Alzheimer disease and abnor-
mally hyperphosphorylated d is the major protein subunit of
PHF [1,2]. However, the mechanisms of phosphorylation of d
and the neurodegeneration in Alzheimer disease are still un-
clear. It has been reported that abnormally hyperphosphory-
lated d strongly inhibits microtubule assembly and is also
present in the a¡ected neurons as amorphous aggregates [3^
5]. Generally, the level of phosphorylation of a protein is
regulated by the equilibrium between the activities of protein
kinases and phosphatases. Previously, regulation of phosphor-
ylation of d has been studied employing SY5Y human neuro-
blastoma cells [6]. Protein phosphatases (PPs), especially PP-
2A and PP-1, were shown to have important roles in the
regulation, and the activities of several protein kinases which
phosphorylate d were also regulated by these protein phospha-
tases [7].
Studies on the protein kinases which phosphorylate d have
also been carried out. At least half of the phosphorylated (Ser/
Thr) sites on d in Alzheimer brains are proline-directed [8].
Proline-directed kinases, including mitogen-activated protein
kinase (MAPK) [9], cyclin-dependent kinase [10], and glyco-
gen synthetase kinase-3 (GSK-3) [11], are known to phosphor-
ylate d at several sites. Among these kinases, GSK-3 has been
most implicated because higher levels of phosphorylation of d
were observed in cells transfected with GSK-3 as compared to
cells transfected with MAPK [12]. Furthermore, GSK-3 has
been co-localized with hyperphosphorylated d in degenerating
neurons in Alzheimer brains and the amount of GSK-3 was
increased in the cytosol fraction [13]. One of the intracellular
signal transduction pathways which might control the GSK-3
activity is the phosphatidylinositol 3-kinase (PI3K) pathway,
which is highly important for the survival of cells, including
neuronal cells [14,15]. Activated PI3K is known to convert
4,5-phosphatidylinositol diphosphates to 3,4,5-phosphatidyl-
inositol triphosphates (PI-TP), and phosphatidylinositol-de-
pendent kinase (PDK) is activated by its binding with 3,4,5-
PI-TP. Activated PDK is able to phosphorylate at Ser-473
and activate protein kinase (PK) B, which is identical to
Akt kinase, and activated PKB is able to phosphorylate
GSK-3 L at Ser-9. Phosphorylation of GSK-3 L at Ser-9 is
known to inhibit its kinase activity [16] (Fig. 1).
The present study shows that in SY5Y human neuroblas-
toma cultured cells wortmannin, an inhibitor of PI3K, results
in apoptosis. During the early phase (1^3 h) the GSK-3 ac-
tivity and the phosphorylation of d were increased, and were
followed by a decrease in the enzymatic activity of GSK-3 to
the basal level and dephosphorylation of d during the late
phase (3^24 h). The inhibition of GSK-3 activity during 3^
24 h resulted from the phosphorylation of GSK-3 by PKC N
which, during the process of apoptosis, was stimulated due to
its cleavage by caspase 3.
2. Materials and methods
2.1. Chemicals and antibodies
Wortmannin and z-DEVD-fmk were purchased from Sigma-Al-
drich (Japan) and from Enzyme System Products (Rivermore, CA,
USA), respectively. GF-109203X was bought from RBI (Natick,
MA, USA). Several phosphorylation-dependent antibodies against d
were employed in this study (Table 1). The Tau-1, PHF-1, M4, and
12E8 antibodies were kindly provided by Drs. L. Binder (North West-
ern University, Chicago, IL, USA), P. Davies (Albert Einstein College
of Medicine, New York, NY, USA), Y. Ihara (Tokyo University,
Tokyo, Japan), and D. Schenk (Athena Neurosciences, San Francisco,
CA, USA), respectively. R127 antibody was previously raised against
a synthetic peptide corresponding to amino acid residues 353^364 of
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GSK-3 L [13]. Anti-caspase 3 antibody was purchased from Upstate
Biotechnology (Lake Placid, NY, USA). Anti-PKC N and a antibodies
were purchased from Santa Cruz Biotechnology (CA, USA). Anti-
protein kinase Akt antibodies (K, L, Q) and phospho-speci¢c anti-
Akt antibody, which is dependent on phosphorylation of PKB at
Ser-473, were purchased from Upstate Biotechnology (Lake Placid,
NY, USA) and New England Biolabs (Beverly, MA, USA), respec-
tively. OPR-1, an anti-GSK-3 L antibody dependent on phosphory-
lation at Ser-9, was generated as follows.
Antisera against synthetic peptide corresponding to the residues 3^
13 (GRPRTSSpFAEG) (Sp : phosphorylated Ser) of the human GSK-
3 L was raised in rabbits. Synthetic phospho- and unphospho-peptides
with an N-terminal cysteine added were prepared by Sawaday Tech-
nology (Tokyo, Japan). They were conjugated to sulfo-SMCC-acti-
vated keyhole limpet hemocyanin (Pierce, IL, USA) and emulsi¢ed
with Freund’s complete adjuvant for the ¢rst immunization and with
Freund’s incomplete adjuvant for the others. Rabbits were immunized
with three serial injections of the phospho-peptide (300 Wg/kg). Anti-
bodies were puri¢ed from the antisera by immunoa⁄nity chromatog-
raphy using the Prot On Kit (Chiron Mimotopes Peptide Systems,
CA, USA). The fractions that bound to the column coupled with
the phospho-peptide were collected and were passed through the col-
umn coupled with the unphospho-peptide. The unbound fractions
were used as Ser-9 phosphorylation-dependent anti-GSK-3 L poly-
clonal antibody, OPR-1. The reactivity of these antibodies was exam-
ined by ELISA and Western blotting.
2.2. Cell line and culture conditions
SH-SY5Y human neuroblastoma cells were obtained from Dr. J.L.
Biedler (Sloan Kettering Institute, New York, NY, USA) and grown
as previously described [6,7].
SY5Y cells were cultured in the absence or the presence of 100 nM,
1 WM or 10 WM of wortmannin. Surviving and dead cells were visu-
alized and counted using the Live/Dead Eukolight Viability/Cytotox-
icity kit (Molecular Probes, Eugene, OR, USA). Apoptotic cells con-
taining fragmented nuclei were also visualized by ethidium
homodimer in the above kit, and counted.
2.3. Western blots
SY5Y cells were lysed in 100 mM PIPES pH 6.8, 2 mM MgCl2, 0.1
mM EDTA, 1 mM PMSF, 5 Wg/ml aprotinin, 5 Wg/ml leupeptin, 25
mM NaF, 1 mM Na3VO4, 0.1% Triton X-100 on ice, and centrifuged
at 200 000Ug for 30 min. The supernatants were employed for the
Western blot analysis and kinase assays. SY5Y cells were cultured in
the presence of 1 WM wortmannin, and harvested after 0, 1, 3, 6, 12 or
24 h. Aliquots of 50 Wg of the supernatants were separated by SDS^
PAGE and transferred to PVDF membranes. As secondary antibodies
alkaline phosphatase-labeled goat anti-mouse or anti-rabbit IgG were
used and membranes were developed by 5-bromo-4-chloro-3-indolyl
phosphate p-toluidine salt and nitroblue tetrazolium chloride except
for the Tau-1 antibody. For the Tau-1 antibody part of the mem-
branes was treated with alkaline phosphatase prior to the application
of primary antibody to visualize total d, and goat anti-mouse antibody
and peroxidase-labeled mouse antibody were used as secondary and
third antibodies, respectively. The membranes were developed with 3-
diaminobenzidine tetrahydrochloride dihydrate. The total levels of
GSK-3 and PKB were visualized using R127 and anti-protein kinase
Akt antibodies (K, L, Q), respectively. The phosphorylation of d was
investigated using phosphorylation-dependent anti-d antibodies as
previously described (Table 1), and the phosphorylation of GSK-3
was studied using OPR-1, the phosphorylation-dependent anti-
GSK-3 L (Ser-9) antibody. The phosphorylation of PKB was inves-
tigated using phospho-speci¢c anti-Akt antibody. The process of
apoptosis was analyzed employing anti-caspase 3 antibody, because
the cleavage is necessary for activation of caspase 3. The degree and
cleavage of PKC N and a were determined by Western blots developed
with anti-PKC N and anti-PKC a antibodies, respectively.
2.4. Protein kinase assays
SY5Y cells were cultured in the presence of 1 WM wortmannin
alone or together with 50 WM z-DEVD-fmk or with 10 WM GF-
109203X, and harvested after 0, 1, 3, 6 or 24 h.
2.4.1. GSK-3. Cell supernatants were prepared, and the GSK-3
activity was assayed using GS-2 phosphopeptide as a kinase substrate
Fig. 1. The phosphatidylinositol 3-kinase (PI3K) pathway. Binding
of insulin to insulin receptor leads to autophosphorylation of the re-
ceptor, and PI3K is activated by binding to the receptor. Activated
PI3K converts 4,5-phosphatidylinositol diphosphates (4,5-PI-DP) to
3,4,5-phosphatidylinositol triphosphates (3,4,5-PI-TP). Phosphatidyl-
inositol-dependent kinase (PDK) is activated by its binding to 3,4,5-
PI-TP, and phosphorylates protein kinase B (PKB). Activated PKB
(by phosphorylation) phosphorylates GSK-3, and inhibits the kinase
activity of GSK-3. Taken together, insulin is able to reduce phos-
phorylation of d through inhibition of GSK-3.
C
Fig. 2. E¡ect of wortmannin on SY5Y cells. A: E¡ect of wortmannin on the percent cell death of SY5Y cells. SY5Y cells were cultured in the
absence or presence of di¡erent concentrations of wortmannin. The percent dead cells was calculated using the total number of cells as 100%.
After 24 h in the presence of di¡erent concentrations of wortmannin, the percent dead cells was dose-dependently increased. B: Western blots
of d in SY5Y cells treated with wortmannin. SY5Y cells were cultured in the presence of 1 WM wortmannin, harvested at di¡erent time points,
and the 200 000Ug supernatants analyzed by Western blotting for d phosphorylation. Phosphorylation levels of d at the PHF-1, M4, and
Tau-1 sites were only increased in the early phase (1^3 h), and then decreased until 24 h. The Tau-1 staining after dephosphorylation (*) of the
membrane shows that total d levels were almost the same at each experimental point. C: Kinase activity of GSK-3 in SY5Y cells treated with
wortmannin. SY5Y cells were cultured in the presence of 1 WM wortmannin and harvested at di¡erent time points. The GSK-3 kinase activity
was assayed in the cell lysates using 10 WM GS-2 phosphopeptide as a substrate. The radioactivity of control cells was normalized as 100%.
GSK-3 activity increased to 172% at 1 h, and decreased thereafter (n = 5). D: Western blots of cell lysates with OPR-1, the phosphorylation-
speci¢c anti-GSK-3 L antibody. Decreased phosphorylation of GSK-3 L was observed at 1 h and the level of phosphorylation increased there-
after. The right panel shows the phosphorylation speci¢city of OPR-1. The antibody stained a 46 kDa band corresponding to GSK-3 L, which
is abolished by the dephosphorylation (*) of the membrane. E: Phosphorylation level of PKB in SY5Y cells treated with wortmannin. Western
blots of cell lysates were developed with phosphorylation-speci¢c anti-PKB antibody. Decreased phosphorylation (i.e. inactivation) of PKB was
observed continuously from 1 h until 24 h. F: Cell death and apoptotic bodies in SY5Y cells treated with wortmannin. Dead cells were in-
creased gradually in cells treated with 1 WM wortmannin (WT) (squares) and with 1 WM wortmannin plus z-DEVD-fmk (WT+DEVD) (circles),
but not in control cells (triangles). Apoptotic bodies were observed in cells treated with 1 WM wortmannin, and z-DEVD-fmk almost com-
pletely blocked the increase of apoptotic cells. When apoptic cells were visualized by 10 WM of Ho«chest 33342, the outcome was similar with
this result (data not shown). G: Activation of caspase 3 visualized by its cleavage. Wortmannin induced the cleavage of caspase 3. The full
length of caspase 3 (MW 32 kDa) (full) was gradually decreased, and its cleaved product (p17) was appeared between 2 and 6 h.
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and (Ala-21)^GS-2 peptide as a background substrate (Upstate Bio-
technology, Lake Placid, NY, USA). The samples were incubated
with the substrates in phosphorylation bu¡er containing 30 mM
Tris pH 7.4, 10 mM MgCl2, 1 mM NaF, 1 mM Na3VO4, 2 mM
EGTA, 10 mM L-mercaptoethanol, 200 WM [32P]ATP at 30‡C for
30 min and the radioactivity incorporated into the peptides was de-
termined as previously described (n = 5) [13,17].
2.4.2. PKC N. Cell supernatants were immunoprecipitated using
anti-PKC N antibody, and immunoprecipitates were incubated with
250 Wg/ml histone H1 (Sigma-Aldrich, Tokyo, Japan) as a substrate
and 10 Wg/ml phosphatidylserine (Sigma-Aldrich, Tokyo, Japan)
(n = 4) [18].
2.4.3. Phosphorylation of GSK-3 by PKC N. SY5Y cells were cul-
tured in the presence of 1 WM wortmannin and harvested after 0, 1 or
3 h. Cell lysates were immunoprecipitated with anti-PKC N antibody
and were incubated with 0.1 units GSK-3 puri¢ed from rabbit muscle
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(Upstate Biotechnology, Lake Placid, NY, USA) as a substrate, in the
enzyme-reactive mixture for PKC described above, at 30‡C for 4 h.
These samples were immunoblotted with OPR-1 to con¢rm the phos-
phorylation of GSK-3 L at Ser-9 by PKC N. The GSK-3 kinase ac-
tivity of the samples was assayed employing GS-2 phosphopeptide as
a substrate as above (n = 4).
3. Results
The e¡ect of wortmannin on the viability of SY5Y cells was
investigated. After 24 h, in the presence of 100 nM, 1 WM and
10 WM wortmannin, the cell death of SY5Y cells was approx-
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imately 30%, 45% and 65% respectively, con¢rming the dose-
dependent cytotoxic e¡ect of wortmannin (Fig. 2A). Western
blot analysis revealed that increased phosphorylation levels of
d at the PHF-1 (Ser-396/404), the Tau-1 (Ser-198/199/202) and
the M4 (Thr-231/Ser-235) sites appeared in the early phase (1^
3 h), and thereafter decreased until 24 h (Fig. 2B). However,
no change of the level of phosphorylation of d at the 12E8 site
(Ser-262/356) was observed (data not shown). To determine
the e¡ect of wortmannin on GSK-3 activity and the level of
phosphorylation of GSK-3 L at Ser-9, SY5Y cells were cul-
tured in the presence of 1 WM wortmannin, and harvested at
0, 1, 3, 6 or 24 h. The GSK-3 activity increased to 170% at 1 h,
and decreased thereafter to the basal level (Fig. 2C). Similarly
a decreased level of phosphorylation of GSK-3 L at Ser-9
was observed at 1 h, but the level increased thereafter with
a time course comparable to that of the changes in the GSK-3
kinase activity (Fig. 2D). These data raised the question of
why wortmannin induced only transient activation of GSK-3.
The decreased activity of GSK-3 beyond 1 h was not due to
the poor stability of wortmannin since fresh supply of the
inhibitor after every 6 h did not change the outcome of this
experiment (data not shown). Furthermore, even though the
cells received only a single treatment with 1 WM wortmannin,
decreased phosphorylation of PKB was observed from 1 until
24 h (Fig. 2E). This implied that although PKB was inhibited
continuously GSK-3 was still inactivated through its phos-
phorylation at Ser-9. Therefore, we examined whether activa-
tion of other kinase(s) led to the change of the phosphory-
lation level of GSK-3 L, and also whether apoptosis was
involved in this cell death process, because apoptosis is known
to induce dramatic biochemical changes including activation
of some kinases. Between 1 and 6 h wortmannin induced cell
death and apoptotic bodies were also increased enormously
between 3 and 6 h (Fig. 2F). The inhibitor of caspase 3, z-
DEVD-fmk, attenuated cell death, and moreover almost com-
pletely inhibited the production of apoptotic bodies, suggest-
ing that apoptosis was involved in this process. In fact acti-
vation of caspase 3 by wortmannin was revealed by the
appearance of p17 (molecular weight 17 kDa), a cleaved frag-
ment of the enzyme, between 2 and 6 h, and this cleavage was
blocked by z-DEVD-fmk (Fig. 2G). Therefore the activated
kinases during apoptosis were studied because the process of
apoptosis is known to induce cleavage of kinases, which is
tightly linked to their enzymatic activation through deletion
of their regulatory domains. Possible cleavage of PKB in
SY5Y cells treated with wortmannin was therefore investi-
gated, but no fragmentation of active PKB was observed in
SY5Y cells (Fig. 2E). Then another candidate pathway, in-
volving PKC, was investigated. According to the homology
study of protein kinases, PKB is a member of the PKC family
and it phosphorylates a RXRXXS sequence motif, while PKC
phosphorylates RXS, RXXS, or RXXSXR motifs and these
are close to the motif of PKB. Indeed, GSK-3 was previously
shown to be phosphorylated by PKC [19,20], and it has been
reported that PKC N and a were cleaved by caspase 3 in cells
in the process of apoptosis [21,22]. Therefore we studied the
possibility of involvement of PKC in regulating GSK-3 activ-
ity in cells treated with wortmannin. After 3 h of treatment
with wortmannin, the fragmentation of PKC N in SY5Y cells
gradually increased (Fig. 3A), but no fragmentation of PKC a
was observed (data not shown). In the presence of z-DEVD-
fmk (an inhibitor of caspase 3) with wortmannin, the frag-
mentation of PKC N disappeared (Fig. 3A). Next it was ex-
amined whether wortmannin a¡ected PKC N activity. SY5Y
cells were cultured in the presence of 1 WM wortmannin and in
the absence or presence of 50 WM z-DEVD-fmk, harvested
after 0, 3 or 6 h, and the PKC N activities were assayed after
immunoprecipitation. The radioactivities of substrate peptides
in the case of control cells were normalized as 100%. Wort-
mannin induced the increase of PKC N activity, but wortman-
Fig. 4. The signal transduction pathway that mediates the regulation
of phosphorylation of d and survival signaling pathways by wort-
mannin in SY5Y cells. In the early phase (0^1 h) GSK-3 is transi-
ently activated by the inactivation of PKB, however in the late
phase (3^24 h) GSK-3 is inactivated by activated PKC N in the pro-
cess of apoptosis.
Fig. 3. Upstream regulation of GSK-3 in SY5Y cells treated with wortmannin. A,B: Western blots of cell lysates developed with anti-PKC N
antibody and PKC N activities in SY5Y cells treated with wortmannin and z-DEVD-fmk. SY5Y cells were cultured in the presence of 1 WM
wortmannin with or without 50 WM DEVD-fmk. A: Cell lysates were immunoblotted with anti-PKC N antibody. Left panel: A main band of
PKC N (90 kDa) (large arrowheads) and an increase of degradative fragments (80 kDa, 60 kDa and 50 kDa) (small arrowheads) after addition
of wortmannin were observed. Right panel: Inhibition of caspase 3 (z-DEVD-fmk) blocked the fragmentation of PKC N. B: SY5Y cells were
cultured in the presence of 1 WM wortmannin with or without 50 WM z-DEVD-fmk, and PKC N was immunoprecipitated. In the absence of z-
DEVD-fmk PKC N kinase activity increased up to 300% (3 h, 6 h), however, in the presence of the caspase 3 inhibitor the kinase activity did
not change (3 h, 6 h) (n = 4). C^E: Phosphorylation and inactivation of puri¢ed GSK-3 by immunoprecipitated PKC N and the e¡ect of PKC
on GSK-3. C: GSK-3 puri¢ed from rabbit muscle (0.1 U) was incubated with PKC N that had been immunoprecipitated from wortmannin (1
WM)-treated cells (0, 1, 3 h). The left lane shows the basal phosphorylation of GSK-3 in the GSK-3 preparation. The phosphorylation of
GSK-3 L at Ser-9 increased upon incubation with immunoprecipitated PKC N from the wortmannin-treated cells (0, 1, 3 h). D: Corresponding
to C, the immunoprecipitated PKC N from cells treated with wortmannin for 3 h also decreased the GSK-3 kinase activity (n = 4). E: In SY5Y
cells that were treated with 1 WM wortmannin and 10 WM GF-109203X, an inhibitor of PKC, the GSK-3 kinase activity increased after 1 h up
to approximately 200%. But in contrast to the cells treated with wortmannin alone (in C) the kinase activity did not decrease thereafter. F,G:
The e¡ect of caspase 3 inhibitor on the cellular GSK-3 activity and phosphorylation of d. F: In SY5Y cells that had been cultured in the pres-
ence of 1 WM wortmannin and 50 WM z-DEVD-fmk, the GSK-3 kinase activity increased in the presence of z-DEVD-fmk, up to approximately
200% at 1 h, and was constant until 24 h. G: Similarly in these cell lysates the phosphorylation of d at the PHF-1 and Tau-1 sites increased at
1 h, and did not change thereafter up to 24 h studied. (*) Immunolabeling of the membrane after prior dephosphorylation shows that the d
content in each lane was constant.
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nin together with z-DEVD-fmk did not (Fig. 3B). To con¢rm
the phosphorylation of GSK-3 by PKC N, GSK-3 puri¢ed
from rabbit muscle was phosphorylated by immunoprecipi-
tated PKC N from wortmannin-treated cells, and the immu-
noreactivity with OPR-1 (phosphorylation at Ser-9) and the
kinase activity were investigated. Indeed, PKC N from the cells
treated with wortmannin for 3 h increased the immunoreac-
tivity of GSK-3 with OPR-1 (Fig. 3C). Corresponding to the
increase in the immunoreactivity with OPR-1, the activity of
the GSK-3 preparation was decreased by PKC N from the
cells treated with wortmannin for 3 h (Fig. 3D). To con¢rm
the e¡ect of PKC on the GSK-3 kinase activity, cells were
treated with 1 WM wortmannin together with 10 WM GF-
109203X, an inhibitor of PKC. In contrast to the cells treated
with wortmannin alone, the GSK-3 activity increased after 1 h
and did not decrease thereafter (Fig. 3E). Furthermore, it was
examined whether PKC N fragmentation might a¡ect GSK-3
activity and phosphorylation of d. When SY5Y cells were
cultured in the presence of wortmannin and z-DEVD-fmk,
and harvested after di¡erent time intervals, the GSK-3 activity
was assayed in cell supernatants. The GSK-3 activity was
increased at 1 h and did not decrease until up to 24 h (Fig.
3F). Being compatible with the time course of the activity of
GSK-3, the phosphorylation of d at the PHF-1, Tau-1 (Fig.
3G) and M4 sites (data not shown) increased at 1 h and
thereafter no dephosphorylation of d was observed during
the 24 h observation period.
4. Discussion
A major biochemical abnormality in Alzheimer disease
brains is the abnormally hyperphosphorylated d, which has
been shown to be phosphorylated by several kinases (for re-
view see [23]). One of these kinases, GSK-3, might be involved
in the mechanism of neurodegeneration in Alzheimer disease,
because in cultured cells transfected GSK-3 e¡ectively phos-
phorylates d [12] and in Alzheimer brains GSK-3 co-localizes
with hyperphosphorylated d in degenerating neurons, and the
levels of GSK-3 are increased by approximately 50% in the
postsynaptosomal supernatants from Alzheimer brains as
compared to controls [13]. One of the intracellular signal
transduction pathways which might control GSK-3 activity
and the phosphorylation of d is the PI3K pathway (Fig. 1),
which has been reported to have a critical role in the survival
of neuronal cells [14,15]. Therefore, employing wortmannin
(an inhibitor of PI3K), which indirectly inhibits PKB and
activates GSK-3, we examined the relationship between cell
death and the phosphorylation of d. In the present study,
wortmannin had cytotoxic e¡ects on SY5Y cells (Fig. 2A),
and actually inhibition of PI3K temporally induced the in-
crease of phosphorylation of d (Fig. 2B). It is known that
GSK-3 alone phosphorylates d at the Tau-1 (Ser-198/199/
202), PHF-1 (Ser-396/404) and M4 (Thr-231/Ser-235) sites,
but not at the 12E8 (Ser-262/356) site in vitro and in vivo
[24,25]. In the present study, the phosphorylation of d was
increased at the same sites in SY5Y cells by wortmannin
(Fig. 2B) and no change in the level of phosphorylation of d
at the 12E8 site was observed throughout the observation
period of 24 h.
The present results suggest that the degree of phosphory-
lation of d is regulated by the PI3K pathway, including GSK-
3. However, we found that the increased levels of phosphor-
ylation of d and GSK-3 activity were observed only in the
early phase but decreased later. And decreased levels of phos-
phorylation of GSK-3 L were observed after 1 h, and the
levels increased thereafter. This increased phosphorylation of
GSK-3 was not due to the instability of wortmannin since
repeated addition of wortmannin to cells caused results sim-
ilar to those with a single dose, nor was it due to a reactiva-
tion of PKB since dephosphorylation of PKB was observed
after the treatment of cells with wortmannin. Therefore acti-
vation of other kinase(s) might have led to these changes in
the level of phosphorylation of GSK-3. Apoptosis is contro-
versial in the neurodegenerative mechanism of Alzheimer dis-
ease and the involvement of apoptosis was also examined in
our experiments. In fact involvement of apoptosis in cells
treated with wortmannin was strongly suggested (Fig.
2F,G). The production of enormous apoptotic bodies, which
implies the activation of endonuclease resulting in fragmented
nuclei, was observed and it was blocked by z-DEVD-fmk, an
inhibitor of caspase 3. The reason for the incomplete inhibi-
tion of cell death by z-DEVD-fmk, in contrast to the complete
inhibition of production of apoptotic bodies, might be ex-
plained probably by a caspase-independent programmed cell
death mechanism which was recently reported [26,27]. The
process of apoptosis is known to induce cleavage of kinases,
which is tightly linked to their enzymatic activation by dele-
tion of their regulatory domain. Thus, in apoptosis, the cleav-
age of the regulatory domain by caspase activates kinases
such as PAK2 and MEKK-1 [28,29]. PAK2 and MEKK-1
phosphorylate p47phox and MKK3/6/7, respectively, and the
sequence motifs of the phosphorylation site by both kinases
di¡er from that of GSK-3 by PKB. Therefore we ¢rst exam-
ined whether through the wortmannin-induced apoptosis PKB
might be proteolysed, and found that in SY5Y cells, no cleav-
age of PKB was observed. Other studies have shown that the
PKC N and a isoforms are activated by the caspase 3 cysteine
protease in cells induced to undergo apoptosis [21,22]. More-
over, it has been reported that GSK-3 L (not K) is phosphor-
ylated in vitro by particular forms of PKC [19,20]. We in-
ferred from this that PKC N or a fragmentation might a¡ect
GSK-3 activity. We found that the treatment of SY5Y cells
with wortmannin for 3 h led to a gradual increase of the
fragmentation of PKC N (Fig. 3A), but not to an increase
of the fragmentation of PKC a (data not shown). Addition
of z-DEVD-fmk (an inhibitor of caspase 3) along with wort-
mannin inhibited fragmentation and activation of PKC N (Fig.
3A,B). The e¡ect of PKC on GSK-3 was con¢rmed in several
ways in this study. Activated PKC N phosphorylated GSK-3
at Ser-9 and inactivated GSK-3 (Fig. 3C,D). In the presence
of GF-109203X, an inhibitor of PKC, wortmannin induced
activation of GSK-3 without consequential inactivation and
also phosphorylation of d without dephosphorylation. These
¢ndings suggested that treatment with wortmannin led to
Table 1
Phosphorylation-dependent anti-d antibodies employed in this study
Antibody Type Epitope Phosphorylated (P)/
non-phosphorylated (N)
Tau-1 mono Ser-198/199/202 N
PHF-1 mono Ser-396/404 P
M4 mono Thr-231/Ser-235 P
12E8 mono Ser-262/356 P
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apoptosis in SY5Y cells, but simultaneously activated the sur-
vival signal pathway, and consequently the generation of ac-
tive PKC N fragment which phosphorylated GSK-3 L and
consequently inhibited the phosphorylation of d (Fig. 4).
Our data show that wortmannin increases the level of d phos-
phorylation by inhibiting the PI3K signal pathway, but later
led to the dephosphorylation of d. In a study of oxidative
stress linked to apoptosis, we have found that hydrogen per-
oxide, arsenite and 4-hydroxy-2-nonenal induced dephosphor-
ylation of d (in preparation) with a basically similar mecha-
nism. The staining of neuronal cells in Alzheimer brains with
the terminal deoxynucleotidyl transferase method [30], and
apoptosis-speci¢c fragmentation of d, actin and amyloid L
precursor protein have been studied [31^33]. However, our
results suggest that a simple mechanism of apoptosis cannot
explain the several-fold increase of hyperphosphorylated d in
Alzheimer brains. If we can assume the co-existence of pro-
apoptotic and anti-apoptotic mechanisms in Alzheimer brains,
the slowly progressive neuronal cell death with huge amounts
of hyperphosphorylated d might be explained. These situa-
tions were experimentally demonstrated in Figs. 2F and 3G
in our present study. The neuronal degeneration in Alzheimer
disease must involve more complicated mechanisms, and fur-
ther studies will be required to clarify this complex process.
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